Irritable bowel syndrome and the gut microbiome: is the microbiome different, do probiotics help, and what does a low-FODMAP diet do?

What it is

Irritable bowel syndrome (IBS) is a common disorder of gut-brain interaction with abdominal pain and altered bowel habits. Studies comparing stool bacteria in people with IBS and healthy controls find few consistent differences; the most consistent in one meta-analysis was lower Bifidobacteria.

What the research says

The evidence is limited and strain-specific. Microbiome differences are small and inconsistent, and these observational studies cannot show whether they cause IBS. Across 82 probiotic trials, only Escherichia strains reached moderate certainty of benefit for global symptoms, and most other strains and blends were rated low or very-low certainty. A low-FODMAP diet ranked first against habitual diet in a network meta-analysis, but another analysis found no clear benefit for global symptoms and noted that few trials used a sham diet. The diet consistently lowers Bifidobacteria, and the long-term meaning of that is unknown.

Evidence grade: Limited evidence.

What goes wrong

Outside IBS trials, the probiotic yeast Saccharomyces boulardii was linked to bloodstream infections in hospital patients, most with digestive disease or recent antibiotics. (Source 1)

• Case-control study, Low certainty.
• Size: 46 fungemia patients.
• Who: Hospital patients in Finland, 2009 to 2018.
• How long: 10 years.
• Result: OR 14 (95% CI 4 to 44); digestive tract disease 59%.
• Funding: Not stated.

The most common underlying condition was a digestive tract disease (59%).

A low-FODMAP diet consistently lowered Bifidobacteria abundance, an adverse microbiome change whose clinical meaning is unknown. (Source 2)

• Meta-analysis, Low certainty.
• Size: 9 RCTs; 403 patients.
• Who: Adults with IBS.
• How long: Short-term.
• Result: Lower Bifidobacteria; no clear effect on diversity or other taxa.
• Funding: Independent (no funding)

A low FODMAP diet consistently led to lower abundance of Bifidobacteria

What the evidence supports

In pooled case-control studies that measured bacteria by culture and PCR, people with IBS had lower Bifidobacteria than healthy controls. (Source 3)

• Meta-analysis, Low certainty.
• Size: Case-control studies (six rated high quality)
• Who: Adults with IBS vs healthy controls, 2000 to 2020.
• How long: Not applicable.
• Result: Bifidobacteria SMD -1.01 (95% CI -2.01 to -0.01)
• Funding: Not stated.

only Bifidobacteria was decreased in irritable bowel syndrome patients compared with healthy controls

Across 82 probiotic RCTs, only Escherichia strains reached moderate certainty of benefit for global IBS symptoms; Lactobacillus strains and Lactobacillus plantarum 299V were low certainty. (Source 4)

• Meta-analysis, Low certainty.
• Size: 82 RCTs; 10,332 patients.
• Who: Adults with IBS.
• How long: Varied by trial.
• Result: Certainty by strain for global symptoms: moderate (Escherichia), low (Lactobacillus, L. plantarum 299V), very low (combinations, Bacillus)
• Funding: Independent (funding: none)

For global symptoms, there was moderate certainty in the evidence for a benefit of Escherichia strains, low certainty for Lactobacillus strains and Lactobacillus plantarum 299V

A separate network meta-analysis ranked Lactobacillus and Bifidobacterium as most effective, while noting few trials at low risk of bias. (Source 5)

• Meta-analysis, Low certainty.
• Size: 76 RCTs; 8,058 participants.
• Who: Adults with IBS.
• How long: Varied.
• Result: Lactobacillus RR 1.74 (95% CI 1.22 to 2.48); Bifidobacterium RR 1.76 (95% CI 1.01 to 3.07)
• Funding: Grant from Chinese Ministry of Science and Technology.

Eight RCTs were classified as low risk of bias. Standard network meta-analysis (NMA) showed that Lactobacillus (RR 1.74, 95% CI 1.22–2.48) and Bifidobacterium (RR 1.76, 95% CI 1.01–3.07) were the most effective for the primary efficacy outcome

A low-FODMAP diet ranked first against habitual diet for global IBS symptoms in a network meta-analysis. (Source 6)

• Meta-analysis, Low certainty.
• Size: 13 RCTs; 944 patients.
• Who: Adults with IBS, mostly secondary or tertiary care.
• How long: Short-term (trial length)
• Result: RR of symptoms not improving 0.67 (95% CI 0.48 to 0.91)
• Funding: Not stated.

a low FODMAP diet ranked first vs habitual diet (RR of symptoms not improving=0.67; 95% CI 0.48 to 0.91, P-score=0.99)

What the evidence does not support

Other commonly cited taxa, including Lactobacillus, showed no significant difference between IBS patients and controls. (Source 3)

• Meta-analysis, Low certainty.
• Size: Case-control studies.
• Who: Adults with IBS vs healthy controls.
• How long: Not applicable.
• Result: No significant differences for Enterococcus, Enterobacter, Lactobacillus, Bacteroides, Escherichia coli.
• Funding: Not stated.

the standardized mean differences of Enterococcus, Enterobacter, Lactobacillus, Bacteroides, and Escherichia coli did not change significantly

Most probiotic trials were at risk of bias, and evidence for combination probiotics and bloating was very low certainty. (Source 4)

• Meta-analysis, Very low certainty.
• Size: 82 RCTs.
• Who: Adults with IBS.
• How long: Varied.
• Result: 24 of 82 RCTs at low risk of bias.
• Funding: Independent (funding: none)

Only 24 RCTs were at low risk of bias across all domains.

Probiotics did not significantly increase adverse events in IBS trials. (Source 4)

• Meta-analysis, Low certainty.
• Size: 55 trials; more than 7,000 patients.
• Who: Adults with IBS.
• How long: Varied.
• Result: Any adverse event not significantly higher; in another analysis 16.4% vs 14.3% on placebo.
• Funding: Independent (funding: none)

The relative risk of experiencing any adverse event, in 55 trials, including more than 7000 patients, was not significantly higher with probiotics.

Compared with placebo, another network meta-analysis found inconsistent results for the low-FODMAP diet: it reduced symptom and pain scores but did not relieve global IBS symptoms, and only one study showed it beat a placebo or sham diet. (Source 5)

• Meta-analysis, Low certainty.
• Size: 8 low-FODMAP trials within 76 RCTs.
• Who: Adults with IBS.
• How long: Short-term.
• Result: Benefit on symptom scores, not global relief.
• Funding: Grant from Chinese Ministry of Science and Technology.

Our NMA showed inconsistent results in the comparison between low FODMAP diet and placebo; the low FODMAP diet exhibited better effects in the reduction of IBS symptom scores or abdominal pain scores, but not the relief of global IBS symptoms.

A low-FODMAP diet did not change total faecal short-chain fatty acids or overall microbiome diversity. (Source 2)

• Meta-analysis, Low certainty.
• Size: 9 RCTs; 403 patients.
• Who: Adults with IBS.
• How long: Short-term.
• Result: No difference in total faecal SCFA.
• Funding: Independent (no funding)

There were no differences in total fecal SCFA concentration between the low FODMAP diet and control diets (standardized mean difference: −0.25; 95% CI: −0.63, 0.13; P = 0.20)

Where the evidence is mixed

Low-FODMAP trials mostly did not study reintroduction and personalisation of FODMAPs, the phases of the diet used in practice. (Source 6)

• Meta-analysis, Low certainty.
• Size: 13 RCTs.
• Who: Adults with IBS.
• How long: Short-term.
• Result: Not applicable.
• Funding: Not stated.

did not study effects of FODMAP reintroduction and personalisation on symptoms

Where the research disagrees

How well the low-FODMAP diet works

• Black, Staudacher and Ford (2022), Network meta-analysis of 13 RCTs: In a network analysis, low FODMAP diet ranked first for all endpoints studied. (Source 6)
• Frontiers in Pharmacology network meta-analysis (2022), Network meta-analysis of 76 RCTs: only one study confirmed that a low FODMAP diet was superior to a placebo or sham diet (Source 5)

How much

• Studied: Probiotic trials tested strains including Lactobacillus plantarum 299V, Saccharomyces cerevisae I-3856, Escherichia strains, Bifidobacterium strains, Bacillus strains and combination products (LacClean Gold S, Duolac 7s). (Source 4)

A common belief, and what the research shows

The belief: Probiotics are proven to fix IBS, and any probiotic will do.

What the research shows: Evidence is strain-specific and mostly low certainty: "For global symptoms, there was moderate certainty in the evidence for a benefit of Escherichia strains, low certainty for Lactobacillus strains and Lactobacillus plantarum 299V, and very low certainty for combination probiotics"

Questions and answers

Is the gut microbiome different in IBS?

Only modestly and inconsistently. In pooled case-control studies, Bifidobacteria were lower in IBS, while Lactobacillus, Bacteroides, E. coli and others did not differ. These are associations, not proof of cause. (Source 3)

Do probiotics help IBS?

Some strains may, but certainty is mostly low or very low and benefits are strain- and symptom-specific. Only 24 of 82 trials were at low risk of bias. Adverse events were not significantly higher than placebo. (Source 4)

Does a low-FODMAP diet work, and what does it do to the microbiome?

It ranked first against habitual diet in one network meta-analysis, but another found no global-symptom benefit and few sham-controlled trials. It consistently lowers Bifidobacteria without changing overall diversity or total SCFAs. (Source 2)

What is it?

IBS is a common gut disorder; its link to the microbiome rests mainly on observational comparisons of stool bacteria. (Source 3)

What does it do in the body?

Microbiome differences in IBS are small and it is not known whether they cause symptoms or result from them. (Source 3)

Is it good or bad for you?

Lower Bifidobacteria is associated with IBS, and the low-FODMAP diet lowers them further; whether this matters clinically is unknown. (Source 2)

How do you get more of it (beneficial bacteria)?

Probiotic trials tested specific strains; evidence of symptom benefit is strain-specific and mostly low certainty. (Source 4)

If it is harmful, what reduces it?

No specific harmful organism is established in IBS in these sources. Rifaximin is used where SIBO is present (see the SIBO topic). (Source 7)

Why might someone be low in it or missing it?

Why people with IBS have lower Bifidobacteria was not explained in the sources reached; a low-FODMAP diet is one documented cause of lower Bifidobacteria. (Source 2)

We searched: Microbiome and diet meta-analyses listed.

Which whole foods contain it or feed it?

Restricting FODMAP-containing foods lowers Bifidobacteria, which suggests these fermentable carbohydrates feed them; the trials did not test specific foods for adding bacteria back. (Source 2)

What happens if you do not have it?

The long-term effect of lower Bifidobacteria in IBS or on a low-FODMAP diet was not established in the sources reached. (Source 2)

We searched: So et al. 2022 meta-analysis; Bu et al. 2022.

How can you test for it, and how reliable is that test?

No validated microbiome test for diagnosing IBS was found; the studies reviewed used research culture and PCR methods. (Source 3)

We searched: Microbiome meta-analyses (Bu 2022); no diagnostic-accuracy study for stool microbiome tests in IBS was reached.

References

1. Emerging Infectious Diseases. Fungemia and Other Fungal Infections Associated with Use of Saccharomyces boulardii Probiotic Supplements. 2021. DOI 10.3201/eid2708.210018. Read the source
2. American Journal of Clinical Nutrition. Effects of a low FODMAP diet on the colonic microbiome in irritable bowel syndrome: a systematic review with meta-analysis. 2022. PMID 35728042. Read the source
3. Turkish Journal of Gastroenterology. Bifidobacteria Was Decreased in Adult Patients With Irritable Bowel Syndrome Based on PCR and Bacterial Culture: A Systematic Review and Meta-Analysis. 2022. PMID 35678794, DOI 10.5152/tjg.2022.21543. Read the source
4. Gastroenterology. Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis. 2023. PMID 37541528. Read the source
5. Frontiers in Pharmacology. Low FODMAP Diet and Probiotics in Irritable Bowel Syndrome: A Systematic Review With Network Meta-analysis. 2022. PMID 35355730, DOI 10.3389/fphar.2022.853011. Read the source
6. Gut. Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis. 2022. Read the source
7. Frontiers in Microbiology. Relationship between small intestinal bacterial overgrowth and irritable bowel syndrome and the efficacy of rifaximin intervention: a systematic review and meta-analysis. 2026. PMID 41883799, DOI 10.3389/fmicb.2026.1780567. Read the source